tbuckley/cabot-search huggingface dataset:
Abstract #LB-152: Fsn0503: A novel Cathepsin S specific antibody that blocks tumour invasion and angiogenesis.
Authors: Shane Olwill, Roberta Burden, Julie Gormley, Donna Small, Claire Ward, Thomas Jaquin, James Johnston, Christopher Scott
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Antibody based drugs represent a major class of therapeutics which have contributed greatly to improved prognostic outcome for patients suffering from many types of cancer. The characteristic target specificity, long half life and reduced toxicity make antibodies attractive modalities for the treatment of neoangiogenesis where long term administration is often necessary. Traditionally antibodies have been developed against targets such as membrane receptors or ligands where they evoke an agonistic / antagonistic response. More recently some groups, including ours, have explored their application in targeting biomarkers, present in the tumour microenvironment, which may originate from more than one tumour associated cell type. Cathepsin S (CatS) is a cysteine protease which has been implicated in tumour angiogenesis with KO models showing an attenuation of tumour growth and reduced vessel formation. During tumour development CatS, normally confined to the lysosomes of professional antigen presenting cells, is secreted into the tumour microenvironment where it is involved in extracellular matrix remodelling. We have developed an antibody, Fsn0503, which specifically targets and inhibits extracellular CatS and have demonstrated efficacy in a range of angiogenesis models. The CatS inhibitory antibody significantly impaired microtubule formation in the in vitro HUVEC assay and ex vivo rat aortic ring assay (p<0.01) . The antibody attenuated HCT116 tumour cell invasion by 64% (p: <0.0001), preventing CatS-mediated extracellular matrix hydrolysis and led to a reduction in tumour mass and metastatic burden in preclinical models. Our data indicates that Fsn0503 is an exciting experimental therapeutic which has great clinical potential.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-152.
Nicolo Paganini. Musical magician and Marfan mutant?
Authors: M. R. Schoenfeld
Journal: JAMA (1978)

The thesis is advanced that Nicolo Paganini of Genoa (1782 to 1840), the greatest violin virtuoso of all time, owed his incomparable violin virtuosity to a fortuitous and fortunate coincidence of three factors: a soaring musical genius, a flair for the dramatic and ostentatious, and manual dexterity conferred by being born with the long fingers and hyperextensible joints of Marfan's syndrome. Ordinarily, an inborn connective tissue disorder is a calamity for the patient and a burden for society. In this particular instance, however, Marfan's syndrome bequeathed to posterity a legacy that will ennoble the human spirit for innumerable generations yet to come. (<i>JAMA</i>239:40-42, 1978)
Treatment of Mild to Moderate Obesity with Laparoscopic Adjustable Gastric Banding or an Intensive Medical Program
Authors: Paul E. O'Brien, John B. Dixon, Cheryl Laurie, Stewart Skinner, Joe Proietto, John McNeil, Boyd Strauss, Sharon Marks, Linda Schachter, Leon Chapman, Margaret Anderson
Journal: Annals of Internal Medicine (2006)

Results: At 2 years, the surgical group had greater weight loss, with a mean of 21.6% (95% CI, 19.3% to 23.9%) of initial weight lost and 87.2% (CI, 77.7% to 96.6%) of excess weight lost, while the nonsurgical group had a loss of 5.5% (CI, 3.2% to 7.9%) of initial weight and 21.8% (CI, 11.9% to 31.6%) of excess weight (P 0.001). The metabolic syndrome was initially present in 15 (38%) patients in each group and was present in 8 (24%) nonsurgical patients and 1 (3%) surgical patient at the completion of the study (P 0.002). Quality of life improved statistically significantly more in the surgical group (8 of 8 subscores of Short Form36) than in the nonsurgical group (3 of 8 subscores). Limitations: The study included mildly and moderately obese participants, was not powered for comparison of adverse events, and examined outcomes only for 24 months. Conclusions: Surgical treatment using laparoscopic adjustable gastric banding was statistically significantly more effective than nonsurgical therapy in reducing weight, resolving the metabolic syndrome, and improving quality of life during a 24-month treatment program.
Abstract 13061: Trends in Incidence, Management and Outcomes of Heart Failure Patients with Cardiogenic Shock
Authors: Navdeep Gupta, Saurabh Aggarwal, Nanzio Gaglianello, Sripal Bangalore, Michael P Cinquegrani
Journal: Circulation (2014)

Background: Patients with heart failure who develop cardiogenic shock or have Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 1 profile have high mortality. However, trends in incidence, management and outcomes of these patients are not well defined. Methods: We analyzed patients in the Nationwide Inpatient Sample (NIS) between 2002-2011 with primary discharge diagnosis of Heart Failure (CHF) and secondary diagnosis of cardiogenic shock. Primary outcome was trend in cardiogenic shock complicating CHF. Secondary outcome was trends in in-hospital mortality. We excluded discharges with co-diagnosis of Acute Myocardial Infarction (AMI) from our analysis. Results: Among 10,475,927 weighted discharges with primary diagnosis of CHF, 349,292 discharges with AMI were eliminated. Of the remaining 10,126,635 discharges, cardiogenic shock was present in 56,314(0.6%). During the study period there was a steady increase in percentage of CHF patients with cardiogenic shock (0.4% in 2002 to 1.0% in 2011, p&lt;0.001). Among patients with cardiogenic shock, the rates of heart transplant showed a steady increase from 2002 at 10.1% to peak in 2008 at 17.8% declining to 14.4% in 2011. Similarly, the rates of left ventricle assist device (LVAD) use showed a steady increase from 1% in 2002 to 11% in 2011. During the same period in-hospital mortality decreased from 44.2% to 26.1% (p&lt;0.001). Conclusions: Cardiogenic shock complicating heart failure has a low but increasing incidence with time. There is a steady increase in the rates of heart transplant and LVAD use in these patients with a steady decline in in-hospital mortality over the ten-year period.
Abstract 871: Clinical utility of a plasma microRNA biomarker within lung cancer screening
Authors: Mattia Boeri, Carla Verri, Gabriella Sozzi, Luca Roz, Davide Conte, Paola Suatoni, Alfonso Marchiano, Carlo L. Vecchia, Marta Rossi, Francesca Bravi, Eva Negri, Nicola Sverzellati, Ugo Pastorino
Journal: Cancer Research (2014)

Abstract Recent screening trials indicate that low-dose computed tomography (LDCT) reduces lung-cancer mortality in high risk subjects. However, high false positive rates, costs and potential harms highlight the need for complementary biomarkers. MicroRNAs (miRNAs) are tissue and disease specific molecules, actively released by cells in the circulatory system, which are associated with protein complexes and/or packaged in exosomes and microvesicles. Circulating miRNAs are rather stable and easily detectable in body fluids suggesting the possibility of using miRNAs as a new promising class of biomarkers. Sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively) of a non-invasive plasma miRNA signature classifier (MSC) to identify lung cancer occurrence and mortality was retrospectively evaluated in samples prospectively collected from smokers within the randomized Multicentre Italian Lung Detection (MILD) trial. Plasma samples from 939 subjects including 69 lung cancer patients and 870 disease-free individuals were analyzed using a Real-Time quantitative PCR (qRT-PCR) based assay for MSC. Combined sensitivity and specificity of plasma MSC and LDCT were assessed in a blinded validation study. MSC correctly identified patients with lung cancer at 87% sensitivity, 81% specificity, and 99% NPV, and 18 of 19 lung cancer deaths at 95% sensitivity 81% specificity, and 99.86% NPV. MSC identified 43 of 49 (88%) LDCT-detected cancers, 8 of 9 (89%) interval cancers in the LDCT arm, and 9 of 11 (82%) cancers in the observational arm. Diagnostic performance of MSC was confirmed by time dependency analysis. MSC fell to negative after lung cancer resection in 16 of 22 evaluable subjects. In lung cancer patients, there was a trend in mortality across levels of MSC (p=0.0336) and survival rate significantly differed according to MSC in all subjects (X21=49.53, p&amp;lt;0.0001). Combination of MSC and LDCT resulted in a 5-fold reduction of LDCT false positive rate. This large validation study highlights the clinical diagnostic and prognostic value of plasma MSC for lung cancer screening in high-risk populations. The combined use of LDCT and MSC could reduce the false positive rate of LDCT improving the efficacy of lung cancer screening. Citation Format: Mattia Boeri, Carla Verri, Gabriella Sozzi, Luca Roz, Davide Conte, Paola Suatoni, Alfonso Marchiano, Carlo La Vecchia, Marta Rossi, Francesca Bravi, Eva Negri, Nicola Sverzellati, Ugo Pastorino. Clinical utility of a plasma microRNA biomarker within lung cancer screening. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 871. doi:10.1158/1538-7445.AM2014-871
THE USE OF CALCIUM ORTHO-IODOXYBENZOATE IN THE TREATMENT OF ARTHRITIS, WITH A DISCUSSION OF ITS POSSIBLE VALUE IN SOME OTHER ORTHOPEDIC CONDITIONS
Authors: Thomas Wheeldon
Journal: Annals of Internal Medicine (1934)

Article1 June 1934THE USE OF CALCIUM ORTHO-IODOXYBENZOATE IN THE TREATMENT OF ARTHRITIS, WITH A DISCUSSION OF ITS POSSIBLE VALUE IN SOME OTHER ORTHOPEDIC CONDITIONSTHOMAS WHEELDON, M.D.THOMAS WHEELDON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-7-12-1540 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSalts of ortho-iodoxybenzoic acid have been used clinically in the treatment of arthritis since 1926 when Young and Youmans1 reported the successful use of ammonium ortho-iodoxybenzoate, given intravenously, in 43 cases. Later Smith2 and Cottrell3 reported some success with the oral administration of calcium ortho-iodoxybenzoate, and this rapidly became the route of choice with the medical profession due to the fact that severe general reactions often followed the intravenous use of the ammonium salt.For two years the writer has been using calcium ortho-iodoxybenzoate as a routine procedure in an investigation comprising a portion of the arthritic cases in his...Bibliography1. YOUNGYOUMANS AGJB: Use of o-iodoxy-benzoic acid in treatment of infectious arthritis, Jr. Am. Med. Assoc., 1926, lxxxvii, 746-752. CrossrefGoogle Scholar2. SMITH M: Use and action of o-iodoxybenzoic acid in treatment of arthritis, Boston Med. and Surg. Jr., 1927, cxcvi, 305-310. CrossrefGoogle Scholar3. COTTRELL JE: Treatment of arthritis with salts of o-iodoxy-benzoic acid, Am. Jr. Med. Sci., 1927, clxxiv, 623-633. Google Scholar4. WHEELDONMAIN TFRJ: Use of colloidal sulphur in treatment of arthritis, Jr. Bone and Joint Surg., 1933, xv, 94-97. Google Scholar5. ARKIN A: On the antiseptic and bactericidal action of the sodium salts of iodbenzoic, iodosobenzoic and iodoxybenzoic acids, Jr. Pharmacol. and Exper. Therap., 1911, iii, 145-154. Google Scholar6. HEKTOEN L: The influence of sodium iodoxybenzoate on the production of antibodies in dogs, Trans. Chicago Path. Soc., 1909-1911, viii, 138-141. Google Scholar7. PEMBERTON R: Arthritis and rheumatoid conditions, 1929, Lea and Febiger, Philadelphia, p. 283. Google Scholar8. TABERN DL: Arthritis and amiodoxyl benzoate, Clin. Med. and Surg., 1928, xxxv, 741-744. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Richmond, Virginia*Received for publication February 6, 1934. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited by2-Iodoxybenzoesäure - ein einfaches Oxidationsmittel mit einer Vielfalt an Anwendungsmöglichkeiten2-Iodoxybenzoic Acid-A Simple Oxidant with a Dazzling Array of Potential Applications 1 June 1934Volume 7, Issue 12Page: 1540-1547KeywordsArthritisCalciumOral administrationOrthopedicsSalts ePublished: 1 December 2008 Issue Published: 1 June 1934 PDF downloadLoading ...
Abstract 2496: Defining the cell surface landscape in cancer: Comprehensive profiling of surface antigens for biomarker discovery and immune monitoring
Authors: Erika A. O'Donnell, Erica L. Alvendia, Benjamin E. Osetek, Tom S. Wehrman, Peter O. Krutzik
Journal: Cancer Research (2014)

Abstract Flow cytometric analysis of surface marker expression is a fundamental component of diagnosis, classification, and monitoring for many hematologic malignancies. However, most clinical implementations of surface immunophenotyping focus on only a handful of markers. A comprehensive survey of CD markers and cell-surface receptors could provide a higher resolution and more accurate characterization of cancer lineages, as well as a better understanding of the immune response to disease progression or therapeutic intervention. To this end, we collated and validated 400 antibodies to known markers and receptors. Antibodies were validated for their performance on live and formaldehyde-stabilized samples to ensure compatibility with standard processing procedures. To establish the baseline and variability of each marker in the normal human population, a protocol was established to co-stain each sample for CD3, CD19, CD16, CD56, and CD14 simultaneously with each of the 400 markers. Differences in antigen abundance and expression frequency were calculated to establish the variation inherent in each marker across the population. To further validate the application of this panel for cancer immunophenotyping, eight commonly studied leukemia and lymphoma cell lines were selected for comprehensive surface characterization. Prior to staining, each cell line was fixed and barcoded with a combination of fluorescent dyes to generate a unique fluorescent signature. This approach allowed multiple cell lines to be combined into a single well for staining and analysis, enabling the rapid evaluation of hundreds of surface antigens using less than five million cells from each line. These studies have resulted in the optimization of a protocol and antibody panel for use in profiling surface protein expression on fixed human blood cells and cell lines. Application of this procedure to clinical samples may provide information useful for biomarker discovery, improved stratification of hematologic malignancies, and the identification of new drug targets. Citation Format: Erika A. O'Donnell, Erica L. Alvendia, Benjamin E. Osetek, Tom S. Wehrman, Peter O. Krutzik. Defining the cell surface landscape in cancer: Comprehensive profiling of surface antigens for biomarker discovery and immune monitoring. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2496. doi:10.1158/1538-7445.AM2014-2496
Subcutaneous panniculitis-like T-cell lymphoma αβ: complete sustained remission with corticosteroids and methotrexate
Authors: H. Briki, J.D. Bouaziz, V. Molinier-Frenkel, M.-H. Delfau-Larue, N. Ortonne, M. Bagot
Journal: British Journal of Dermatology (2010)

Conflicts of interest: none declared. Madam, The subcutaneous panniculitis‐like T‐cell lymphoma (SPTL) was defined as a distinct entity by the World Health Organization (WHO) classification in 20051 and this definition was adopted by the WHO classification in 2008.2 In this classification the term 'SPTL' was used only for cases with a αβ T‐cell phenotype whereas cases with a γδ T‐cell phenotype were included in the category of cutaneous γδ T‐cell lymphomas that display a much more aggressive clinical course.3, 4 Recent studies suggest that the disease course in patients with SPTL could be controlled for long periods of time with systemic corticosteroids instead of doxorubicin‐based chemotherapies.3, 5, 6 We report four cases of patients with SPTL‐αβ treated with corticosteroids, methotrexate, or a combination of both treatments, who achieved a long‐term complete remission. Patient 1 is a 14‐year‐old female who had subcutaneous nodules of the abdominal wall and thigh (Fig. 1a) with fever and lymphopenia (100 lymphocytes mm−3). Histologically, there was a lobular lymphocytic infiltrate in the subcutaneous fat with atypical pleomorphic lymphocytes (Fig. 1b) CD3+, CD8+ (Fig. 1c), CD56− and granzyme B+. γ‐Polymerase chain reaction (PCR) performed in the skin was positive without T‐cell receptor δ‐chain gene rearrangement. Treatment with 1 mg kg−1 per day of oral prednisone was initiated for 1 month then gradually tapered and stopped after 7 months allowing total remission after 14 months of follow‐up.
Commentary: Using patients' narratives in complex research
Authors: Ross E G Upshur
Journal: BMJ (2005)

ers) has written of the powerful link between storytelling in group situations and subsequent action by individual participants. 16Because of the detailed analysis of what actually went on in the groups, this study has contributed considerably to the research literature on group based education in diabetes (summarised on bmj.com).This study has provided unique insights into the feasibility of setting up diabetes support and education groups for both bilingual health advocates and service users and into the process of learning, empowerment, and change in such groups.The impact of the intervention should now be tested in a randomised controlled trial.We thank the service users, bilingual health advocates, and many other stakeholders who participated so enthusiastically in setting up and evaluating the groups described here.Their names are listed in the "Sharing stories" workbook.We especially thank John Eversley, Jill Russell, Anita Berlin, and Farida Malik for conceptual and practical input at different stages.
Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole
Authors: F. Bosma, A. Voss, H.W. van Hamersvelt, R.G.L. de Sévaux, J. Biert, B.J. Kullberg, W.G.J. Melchers, P.E. Verweij
Journal: Clinical Microbiology and Infection (2003)
Serial Passage of a Lymphocytic Tumor and Choriomeningitis Virus in Immune Mice
Authors: Victor H. Haas
Journal: JNCI Journal of the National Cancer Institute (1960)

Lymphocytic choriomeningitis (LCM) virus associated with an ascitic form of the lymphocytic tumor P288 survived indefinite serial passage in LCM-immune strain CDBA mice. Initially it was necessary to treat the mice with amethopterin (methotrexate), but after repeated passage the virus survived in untreated immune mice with intraperitoneal, but not with subcutaneous, tumors. In immune Swiss mice, where the tumor normally regresses, amethopterin enabled both tumor and virus to survive if the tumor was in the ascitic form. In immune Swiss mice not treated with amethopterin, the LGM-carrying tumor from 2 passage lines behaved differently; the tumor that had been maintained in amethopterin-treated immune CDBA mice did not support LCM survival, but the tumor adapted to passage in untreated immune CDBA mice supported LCM survival during the early stages of ascites tumor growth. The explanation offered for the survival of LCM in immune mice under these conditions is that virus passes from one tumor cell to its offspring at the time of cell division. Similarities between these LCM tumor-cell relationships and several other virus-cell interactions are discussed.
Drug points: Exacerbation of idiopathic Parkinson's disease by naproxen
Authors: S Shaunak, P Brown, J A Morgan-Hughes
Journal: BMJ (1995)

Drs S SHAUNAK, P BROWN, and J A MORGAN-HUGHES (National Hospital for Neurology and Neurosurgery, London WC1N 3BG) write: A 74 year old woman with a 10 year history of idiopathic Parkinson's disease was prescribed naproxen 250 mg three times a day for musculoskeletal pain. Her symptoms had previously been well controlled with co-beneldopa (levodopa and benserazide hydrochloride) 375 mg a day, selegiline 10 mg a day, and propranolol 60 mg a day. Shortly after starting naproxen treatment she became immobile …
Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein
Authors: Victoria L. M. Herrera, Savvas C. Makrides, Hou Xiang Xie, Hedy Adari, Ronald M. Krauss, Una S. Ryan, Nelson Ruiz-Opazo
Journal: Nature Medicine (1999)
NONSPECIFIC GRANULOMA OF THE INTESTINE CAUSING INTESTINAL OBSTRUCTION
Authors: T. Homer Coffen
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3558: Cardiac Contractility Modulation Improves Exercise Tolerance in NYHA Class III Patients With Narrow QRS and EF Between 25 and 35%: A Subgroup Analysis of the FIX-HF-5 Study
Authors: Alan H Kadish, Koonlawee Nademanee, Kent Volosin, Steven Krueger, Suresh Neelagaru, Nirav Raval, Owen Obel, Stanislav Weiner, Marc Wish, Peter Carson, Kenneth Ellenbogen, Robert Bourge, Michael Parides, Richard Chiacchierini, Rochelle Goldsmith, Sidney Goldstein, Yuval Mika, Daniel Burkhoff, William Abraham
Journal: Circulation (2009)